Free Trial
OTCMKTS:CZMWY

Carl Zeiss Meditec (CZMWY) Stock Price, News & Analysis

Carl Zeiss Meditec logo
$65.79 -1.73 (-2.56%)
As of 02:42 PM Eastern

About Carl Zeiss Meditec Stock (OTCMKTS:CZMWY)

Key Stats

Today's Range
$65.52
$66.04
50-Day Range
$53.34
$75.74
52-Week Range
$46.13
$97.09
Volume
746 shs
Average Volume
5,176 shs
Market Capitalization
N/A
P/E Ratio
71.51
Dividend Yield
0.46%
Price Target
N/A
Consensus Rating
Hold

Company Overview

Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, such as ametropia (refraction), cataracts, glaucoma, and renital disorders. This segment also provides devices for general ophthalmological examination and care, including slit lamps, refractometers, tonometers, optical coherence tomography devices, and fundus cameras; and devices for functional diagnostics (perimeters), as well as digital products for storage, evaluation, and sharing of clinical data. In addition, this segment offers surgical ophthalmology products comprising surgical microscopes, biometers, phacoemulsification, and vitrectomy devices; intraocular lenses for cataract patients; and systems and consumables for laser eye surgery. The Microsurgery segment provides products and solutions for invasive surgical treatments; and solutions in the area of ear, nose and throat, plastic and reconstructive, neuro, dental, and spinal surgeries. It serves physicians in various fields and hospitals. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG.

Carl Zeiss Meditec Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
1st Percentile Overall Score

CZMWY MarketRank™: 

Carl Zeiss Meditec scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Carl Zeiss Meditec is 71.51, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.84.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Carl Zeiss Meditec is 71.51, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.89.

  • Read more about Carl Zeiss Meditec's valuation and earnings.
  • Percentage of Shares Shorted

  • Short Interest Ratio / Days to Cover

    Carl Zeiss Meditec has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Carl Zeiss Meditec has recently increased by 200.00%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Carl Zeiss Meditec pays a meaningful dividend of 1.36%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Carl Zeiss Meditec does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Carl Zeiss Meditec is 32.64%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Read more about Carl Zeiss Meditec's dividend.
  • Percentage of Shares Shorted

  • Short Interest Ratio / Days to Cover

    Carl Zeiss Meditec has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Carl Zeiss Meditec has recently increased by 200.00%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Carl Zeiss Meditec this week, compared to 0 articles on an average week.
Receive CZMWY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Carl Zeiss Meditec and its competitors with MarketBeat's FREE daily newsletter.

CZMWY Stock News Headlines

Trump’s Bitcoin Reserve is No Accident…
For the first time in history, we have a president who understands crypto's potential to bypass the banking system entirely. And Wall Street's biggest players know it. I've created a blueprint revealing how everyday investors can turn this historic shift into potentially life-changing wealth. Like the 75,000 new millionaires created in the last bull run— only this time with institutional backing.
See More Headlines

CZMWY Stock Analysis - Frequently Asked Questions

Carl Zeiss Meditec's stock was trading at $47.50 at the start of the year. Since then, CZMWY shares have increased by 38.5% and is now trading at $65.79.
View the best growth stocks for 2025 here
.

Shares of CZMWY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Record date for 4/15 Dividend
3/28/2025
Ex-Dividend for 4/15 Dividend
3/28/2025
Dividend Payable
4/15/2025
Today
5/28/2025
Next Earnings (Estimated)
8/07/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Medical Instruments & Supplies
Sub-Industry
N/A
Current Symbol
OTCMKTS:CZMWY
CIK
N/A
Fax
N/A
Employees
4,823
Year Founded
N/A

Profitability

Trailing P/E Ratio
73.39
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (OTCMKTS:CZMWY) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners